JOHNSON B KRISTINE 4

What Happened
Kristine B. Johnson, a director of ClearPoint Neuro, had 12,417 restricted stock units (RSUs) settle into 12,417 shares of ClearPoint Neuro common stock on May 19, 2026. The Form 4 shows an exercise/conversion of a derivative (Transaction Code M) and the corresponding issuance of shares; no per-share price or cash value is reported in the filing. This was the scheduled vesting/settlement of an award rather than an open‑market purchase or sale.

Key Details

• Transaction date: May 19, 2026 (reported on Form 4 filed May 21, 2026). Filing appears timely.
• Shares acquired: 12,417 shares (settlement of RSUs). The filing also records the cancellation/conversion of 12,417 derivative units.
• Price/Value: N/A in the filing (no cash consideration reported).
• Footnote: The RSUs were originally granted May 22, 2025 and vested on the earlier of the first anniversary of the grant or the day before the company’s 2026 annual meeting; this transaction represents the scheduled settlement of those RSUs.
• Shares owned after transaction: not specified in this filing.

Context
This transaction reflects routine equity compensation vesting for a director (an award settlement), not a purchase or sale that signals a change in conviction. For derivative entries, the M code here denotes conversion/exercise of a derivative (RSU → common shares). No immediate sale or cashless exercise is indicated.